Background: The distinction between malignant and benign thyroid oncocytic cell tumors (OCTs) before and during surgery still represents a diagnostic challenge. We focused on the search for specific factors that predict malignancy and influence the prognosis of OCTs, and for their most appropriate management.
Methods: From January 1998 to May 2007, 57 patients underwent thyroidectomy in our surgical department because of OCT. A cross-sectional study of 28 patients with carcinoma and 29 patients with adenoma was performed: demographic data, tumor characteristics, diagnostic results, patient management, postoperative, and follow-up results were evaluated.
Results: The prevalence of malignancy was 49.1%. The mean tumor size was significantly greater for carcinomas than for adenomas (3.0 cm vs. 1.8 cm; p = 0.003). Threshold sizes of more than 3.0 cm and 4.0 cm were significant for predicting malignancy (p = 0.020 and p = 0.010, respectively). Tumor multifocality, microfollicular features, and severe cytological atypia also were significantly related to malignancy (p = 0.012 and p = 0.025, respectively). Recurrent OCT was observed in three patients with carcinoma. One patient with distant metastases died from the disease. Older age, tumor size, thyroid capsular invasion, higher TNM stage, and AMES high risk were factors significantly related to tumor recurrence. Multivariate analysis showed that larger tumor size was the only factor predictive of malignancy and influencing recurrence.
Conclusions: All OCTs should be referred to surgery because of the high prevalence of malignancy. In the case of OCTs with larger tumor size and microfollicular features with severe cytological atypia, total thyroidectomy is strongly recommended as initial treatment also in relation with the more likely aggressive biological behavior of greater tumors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00268-009-0357-z | DOI Listing |
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, 11829, Cairo, Egypt.
Antibody-drug conjugates (ADCs) have emerged as a promising strategy in targeted cancer therapy, enabling the precise delivery of cytotoxic agents to tumor sites while minimizing systemic toxicity. However, traditional ADCs face significant limitations, including restricted drug loading capacity, where an optimal drug-to-antibody ratio (DAR) is crucial; low DARs may lead to insufficient potency, while high DARs can cause rapid clearance and increased toxicity. Additionally, ADCs often suffer from instability in circulation due to the potential for premature release of cytotoxic agents, resulting in off-target effects and reduced therapeutic efficacy.
View Article and Find Full Text PDFAnal Chem
January 2025
State Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun 130012, China.
As the most common and lethal cancer of the female gonads, ovarian cancer (OC) has a grave impact on people's health. OC is asymptomatic, insidious in onset, difficult to diagnose and treat, fast-growing, and easy to metastasize and has poor prognosis and high mortality. How to detect OC as early as possible and treat it without side effects has become a challenging medical problem.
View Article and Find Full Text PDFBreast Cancer Res
January 2025
Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, 246 Clayton Road, Clayton, VIC, 3168, Australia.
Background: Tumour DNA methylation has been investigated as a potential marker for breast cancer survival, but findings often lack replication across studies.
Methods: This study sought to replicate previously reported associations for individual CpG sites and multi-CpG signatures using an Australian sample of 425 women with breast cancer from the Melbourne Collaborative Cohort Study (MCCS). Candidate methylation sites (N = 22) and signatures (N = 3) potentially associated with breast cancer survival were identified from five prior studies that used The Cancer Genome Atlas (TCGA) methylation dataset, which shares key characteristics with the MCCS: comparable sample size, tissue type (formalin-fixed paraffin-embedded; FFPE), technology (Illumina HumanMethylation450 array), and participant characteristics (age, ancestry, and disease subtype and severity).
Endocrine
January 2025
Anatomic Pathology - Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
Purpose: Adrenal vascular tumors are mainly represented by adrenal cavernous hemangiomas (ACHs) and adrenal cystic lymphangiomas (ACLs). Their radiological features often overlap with malignant tumors, therefore ruling out malignancy becomes mandatory. We analyzed clinical, radiological, and histopathological data to identify specific characteristics of these tumors.
View Article and Find Full Text PDFEur Spine J
January 2025
Department of Neurosurgery, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Background: Giant sacral and presacral schwannomas are very rare conditions and their prevalence is estimated to account for only 0.3 to 3.3% of overall schwannomas.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!